ATRC Earnings Date: Nov 3, 2026 (Estimated) — AtriCure, Inc.
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is ATRC's next earnings date?
AtriCure, Inc. (ATRC) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.05 on revenue of $151.0M.
How did ATRC do in its last earnings report?
In its most recent report on Jul 23, 2026 (Q2 2026), AtriCure, Inc. posted EPS of $0.18 versus the $0.03 estimate, a beat of 500.0%. Revenue was $153.6M against a $151.8M estimate. The stock's 1-day post-earnings move was +6.2%.
How much does ATRC stock move after earnings?
ATRC beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.8% (up or down) in the day after earnings.
About AtriCure, Inc.
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-23 | Q2 2026 | 0.03 | 0.18 | +500.00% | $153.6M | ✅ Beat | +6.18% | +21.67% | +48.42% |
| 2026-05-05 | Q1 2026 | -0.06 | 0.00 | +100.00% | $141.2M | ✅ Beat | -4.70% | -9.19% | -7.21% |
| 2026-02-17 | Q4 2025 | -0.04 | 0.06 | +250.00% | $140.5M | ✅ Beat | -2.15% | -5.55% | -12.50% |
| 2025-10-29 | Q3 2025 | -0.11 | -0.01 | +90.91% | $134.3M | ✅ Beat | -3.81% | -8.80% | +1.92% |
| 2025-07-29 | Q2 2025 | -0.16 | -0.02 | +87.50% | $136.1M | ✅ Beat | +10.72% | +18.31% | +17.55% |
| 2025-02-12 | Q4 2024 | -0.15 | -0.08 | +46.67% | $124.3M | ✅ Beat | -6.54% | -7.55% | -21.36% |
| 2024-10-29 | Q3 2024 | -0.19 | -0.17 | +10.53% | $115.9M | ✅ Beat | +18.35% | +20.52% | +22.90% |
| 2024-07-30 | Q2 2024 | -0.17 | -0.17 | +0.00% | $116.3M | ➖ Inline | -1.95% | -2.00% | +16.36% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $153.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| U [S] | 81.8% | $125.6M | +13.6% | $101.6M | $101.1M | $110.6M | $109.3M |
| Non Us | 18.2% | $28.0M | +9.6% | $22.7M | $22.5M | $25.6M | $25.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.